Nail Changes in Connective Tissue Diseases
Nail changes in connective tissue diseases (CTDs), including systemic sclerosis (SSc), dermatomyositis (DM), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD), reflect a combination of peripheral microvascular damage and systemic autoimmune inflammation.
The nail unit, and especially the proximal nail fold, is the only place on the body where the microcirculation can be viewed directly, using nailfold capillaroscopy (NFC). Capillary changes here appear very early, often before systemic symptoms have fully developed.
- Microvascular Changes and Nail Ischemia:
- Injury to the vessel lining (endothelium) leads to intimal thickening, microthrombi and persistent vasospasm (Raynaud phenomenon).
- Chronic poor blood supply to the nail matrix and nail bed reduces keratin production, causing thin nail plates, longitudinal ridges, brittleness and splitting.
- Pterygium Inversum Unguis (PIU):
- In scleroderma, fibrosis of the nail bed makes the epithelium stick firmly to the underside of the nail plate at its free edge.
- As the nail grows out, it drags the nail bed epithelium along, obliterating the distal subungual groove and making nail trimming very painful.
- Resorption of the Fingertip Bone (Acro-osteolysis) and Beaked Nails:
- Severe, long-standing ischemia causes the tuft of the distal phalanx to be reabsorbed.
- The soft tissue around the nail contracts, so the nail plate curls downward over the shrunken fingertip, producing "beaked" nails (claw-like dystrophy).
Nailfold capillaroscopy (NFC) is an essential noninvasive test and is part of the ACR/EULAR classification criteria for systemic sclerosis. In a patient with Raynaud phenomenon, a scleroderma pattern (giant capillaries, capillary loss and avascular areas) signals a risk of progressing to systemic sclerosis or dermatomyositis. At Haute-Derma, every nail assessment includes digital NFC at 200x magnification so we can pick up microvascular damage while it is still subclinical.
Clinical Signs by Underlying Disease
Systemic Sclerosis (SSc)
- Pterygium inversum unguis (PIU): The nail bed epithelium sticks to the underside of the nail plate and is stretched out to the free edge.
- Pitting scars and digital ulcers: Small, deep, pinpoint atrophic scars on the fingertips caused by ischemic necrosis.
- Beaked nails: The nail plate curves over a fingertip that has shrunk because of bone resorption (acro-osteolysis).
- Capillaroscopy (Scleroderma Pattern): Divided into three stages:
- Early: Giant capillaries (> 50 µm), few hemorrhages.
- Active: Many giant capillaries, widespread microhemorrhages and early capillary loss.
- Late: Extensive avascular areas and abnormal new vessel growth (neoangiogenesis, bushy capillaries).
Dermatomyositis (DM)
- Keining sign (ragged cuticles): The cuticle becomes thickened, rough, scaly and cracked, with painful pinpoint red microhemorrhages in the proximal nail fold.
- Periungual erythema and telangiectasia: The skin around the nail fold turns bright red or violaceous, and dilated, tortuous capillary loops are visible to the naked eye or with a magnifier.
- Periungual Gottron papules: Shiny pink-red papules over the distal interphalangeal joints and nail folds.
Systemic Lupus Erythematosus (SLE)
- Red lunula: The lunula turns orange-red or red with a pink rim because of dilated, inflamed vessels beneath it.
- Splinter hemorrhages: Thin brown or black longitudinal streaks of blood under the nail plate, caused by vasculitis of the nail bed.
- Nailfold capillaries in SLE: Capillaries are often elongated and twisted (tortuous capillaries) but the overall architecture is preserved, and large avascular areas like those in SSc are uncommon.
Evaluation and Treatment at Haute-Derma
Treating nail involvement in connective tissue disease requires both vasodilators to improve the microcirculation and systemic immunomodulating or immunosuppressive drugs.
Initial Assessment and Screening
- Nailfold capillaroscopy (NFC): Measures capillary density (normally 7–10 loops per mm) and looks for giant loops and avascular areas.
- Autoantibody testing: ANA, anti-dsDNA, anti-Scl-70, anti-centromere, anti-MDA5, anti-Jo-1.
Vasodilator Therapy and Microvascular Protection
- Calcium channel blockers (CCBs, first line):
- Nifedipine ER 30–60 mg/day or amlodipine 5–10 mg/day to reduce how often Raynaud attacks occur.
- Phosphodiesterase-5 (PDE-5) inhibitors:
- Sildenafil 25–50 mg or tadalafil 10–20 mg/day lowers the risk of digital ulcers and improves blood supply to the nail matrix.
- Intravenous prostanoids (iloprost):
- Used for severe Raynaud phenomenon, necrotic digital ulcers or rapidly spreading avascular areas in the nail fold (0.5–2.0 ng/kg/min as a continuous infusion for 3–5 days).
Systemic Immunomodulating Therapy
- Hydroxychloroquine (HCQ):
- 200–400 mg/day (< 5 mg/kg/day). The cornerstone of SLE treatment and of mild periungual inflammation.
- Mycophenolate mofetil (MMF) / methotrexate:
- MMF (2–3 g/day) helps slow skin and nail fibrosis in systemic sclerosis.
- Methotrexate (15–20 mg/week) is preferred for dermatomyositis with nail fold involvement.
- Targeted biologics:
- Rituximab (anti-CD20): Clearly improves microvascular perfusion and digital ulcer healing in refractory scleroderma and dermatomyositis.
- Tocilizumab (anti-IL-6R): Helps halt progressive fibrosis of the soft tissue around the nail.
